Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM)

Sanctuary Advisors LLC acquired a new position in Iterum Therapeutics plc (NASDAQ:ITRM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $35,000. Sanctuary Advisors LLC owned about 0.07% of Iterum Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in Iterum Therapeutics during the 3rd quarter valued at $36,000. Lee Financial Co bought a new stake in Iterum Therapeutics during the 4th quarter valued at $28,000. Finally, Apollon Financial LLC raised its holdings in Iterum Therapeutics by 11.3% during the 4th quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock valued at $443,000 after buying an additional 25,500 shares during the last quarter. 9.21% of the stock is currently owned by institutional investors.

Iterum Therapeutics Stock Up 0.7 %

NASDAQ:ITRM opened at $1.37 on Friday. The company has a fifty day moving average of $1.57 and a 200 day moving average of $1.47. Iterum Therapeutics plc has a 52 week low of $0.81 and a 52 week high of $3.02. The firm has a market capitalization of $47.38 million, a P/E ratio of -1.05 and a beta of 2.44.

Iterum Therapeutics Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.